R. Lambkin

Publications20
h-index12
Citations1,014
Highly Influential Citations20
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • R. Webster
  • 934 Publications, 80,084 Citations
  • J. Oxford
  • 278 Publications, 8,545 Citations
  • F. Hayden
  • 461 Publications, 40,120 Citations
  • L. Gubareva
  • 195 Publications, 16,592 Citations
  • Publications
  • Influence
The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo.
Oseltamivir carboxylate is a potent and specific inhibitor of influenza A and B neuraminidase (NA). Oseltamivir phosphate, the ethyl ester prodrug of oseltamivir carboxylate, is the first orally… Expand
  • 358
  • 8
Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo.
Oseltamivir phosphate (Tamiflu, Ro 64-0796) is the first orally administered neuraminidase (NA) inhibitor approved for use in treatment and prevention of influenza virus infection in man. Oseltamivir… Expand
  • 169
  • 5
Treatment of epidemic and pandemic influenza with neuraminidase and M2 proton channel inhibitors.
A small armentarium of anti-influenza drugs now exists, and includes the M2 blockers (amantadine and rimantadine) and the neuraminidase inhibitors (Relenza and Tamiflu). The neuraminidase inhibitors… Expand
  • 191
  • 3
  • PDF
Neutralization escape mutants of type A influenza virus are readily selected by antisera from mice immunized with whole virus: a possible mechanism for antigenic drift.
It is not fully understood how antigenic drift of the haemagglutinin of type A influenza virus in man occurs in the presence of the expected polyclonal antibody response to the five antigenic sites,… Expand
  • 74
  • 1
Interfering vaccine (defective interfering influenza A virus) protects ferrets from influenza, and allows them to develop solid immunity to reinfection.
Defective interfering (DI) virus RNAs result from major deletions in full-length viral RNAs that occur spontaneously during de novo RNA synthesis. These RNAs are packaged into virions that are by… Expand
  • 33
  • 1
A new infectious disease challenge: Urbani severe acute respiratory syndrome (SARS) associated coronavirus
Most community acquired pneumonias are bacterial and the hospitalised patient, often elderly, is rapidly rendered pathogen free by broad spectrum antibiotics. There is no particular threat of… Expand
  • 19
  • 1
  • PDF
New Antiviral Drugs, Vaccines and Classic Public Health Interventions against SARS Coronavirus
Severe acute respiratory syndrome (SARS) is caused by one of two recently discovered coronaviruses. The virus is emergent from South East (SE) Asian mammals: either the civet cat, a related species… Expand
  • 9
  • 1
New Millennium Antivirals against Pandemic and Epidemic Influenza: The Neuraminidase Inhibitors
The mushroom shaped outer spike protein of influenza, neuraminidase, was first discovered nearly 60 years ago. Its importance in viral replication was soon recognised both at the point of viral… Expand
  • 24
A Throat Lozenge Containing Amyl Meta Cresol and Dichlorobenzyl Alcohol Has a Direct Virucidal Effect on Respiratory Syncytial Virus, Influenza a and SARS-CoV
A potent virucidal mixture containing amyl metacresol and dichlorobenzyl alcohol at low pH inactivated enveloped respiratory viruses influenza A, respiratory synctial virus (RSV) and severe acute… Expand
  • 26
All rabbits immunized with type A influenza virions have a serum haemagglutination-inhibition antibody response biased to a single epitope in antigenic site B.
Nine rabbits were immunized with type A influenza virions and the epitope specificities of the secondary serum haemagglutination-inhibition (HI) antibody response were analysed with a panel of… Expand
  • 22